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Interstitial deletions of the long arm of chromosome 13 (13q) are related with variable phenotypes, according to
the size and the location of the deleted region. The main clinical features are moderate/severe mental and growth
retardation, cranio-facial dysmorphism, variable congenital defects and increased susceptibility to tumors. Here we
report a 3-year-old girl carrying a de novo 13q13.3-21.32 interstitial deletion. She showed developmental delay,
growth retardation and mild dysmorphism including curly hair, high forehead, short nose, thin upper lip and long
philtrum. An abnormal mass was surgically removed from her liver resulting in a hemangioendothelioma. Array
analysis allowed us to define a deleted region of about 27.87 Mb, which includes the RB1 gene. This is the first
report of a 13q deletion associated with infantile hemangioendothelioma of the liver.
Keywords: RB1, Tumor, Hemangioendothelioma, Liver, Chromosome 13q, Deletion, SyndromeBackground
Chromosome 13 has one of the lowest gene densities, al-
though several tumor suppressor genes are present on the
long arm and are involved in different types of tumors
such as breast cancer (BRCA2), alveolar rhabdomyosar-
coma (FOXO1A) and retinoblastoma (RB1) [1]. The 13q
deletion syndrome was first described as a distinct entity
in 1969 in patients with mental and growth retardation
associated with retinoblastoma (Rb) [2]. Because of
the highly variable clinical features associated with 13q
deletion, there has been a growing interest in defining
genotype-phenotype correlations. The first classification
was proposed by Brown and coworkers, who delineated
three groups: group 1 with proximal deletions not exten-
ding into q32; group 2 with distal deletions including at
least part of q32; distal deletions involving q33-q34 [3].
Recently, Mitter et al. analyzed a cohort of 63 patients
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reproduction in any medium, provided the orproposed a classification based on three different groups:
patients with a small deletion (within 13q14 and smaller
than 6 Mb or normal karyotype), patients with a medium
deletion (within 13q12.3q21.2 and size 6–20 Mb) and pa-
tients with a large deletion (within 13q12q31.2 and larger
than 20 Mb). Notably, patients with 13q14.2 deletion
involving the tumor suppressor gene RB1 are at high risk
to develop Rb as well as other tumors [4]. We describe a
3-year-old girl with a 27.87 Mb deletion of the long arm
of chromosome 13 with hemangioendotelioma of the
liver.Case report
The patient is a female dizygotic twin born to unrelated
healthy parents who underwent assisted reproductive
technology. Pregnancy was complicated by gestational
diabetes detected at 25 weeks of gestation by oral
glucose-tolerance test and managed with a diet inter-
vention. Prenatal ultrasound examination did not reveal
any abnormality and growth parameters were within
normal range. Amniocentesis was not performed. At the
time of delivery her father was 39 years and her mother
34. The patient was born at 37 weeks by caesarean sec-
tion for breech presentation with birth weight 2980 grtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cumference 36 cm (90th centile). Her Apgar scores were
7 and 8 at 1 and 5 minutes. Hypotonia was present at
birth, while brain ultrasound was normal. She mani-
fested neonatal infection, treated with amoxicillin for
5 days. At the age of 5 months a severe gastroesophageal
reflux disease was diagnosed. Abdominal ultrasono-
graphy was performed to exclude the presence of uro-
genital malformations. At the age of 1 year, growth
retardation was noted. Laboratory exams showed nor-
mal thyroid function and screening for celiac disease
was negative. She was admitted to our endocrinology
pediatric department at the age of 1 year and 6 months.
Physical examination revealed a height of 71 cm (< 3°
centile, -3 SDS), weight of 8,6 kg (3th centile), and head
circumference of 47 cm (50th centile) according to
sex and age. Craniofacial dysmorphism included long
face with curly, black hair, bilateral epicanthus, broad,
saddles nasal bridge with a long philtrum, thin upper
lip, down-turned corners of the mouth, overgrowth of
the upper alveolar bed and arched palate and mild
micrognathia (Figure 1a,b). Lower and upper limbs
appeared both micromelic, toes were short. Exa-




Figure 1 Craniofacial features and genomic oligo-array data observed
carrying a de novo 13q13.3q21.31 interstitial deletion long face with curly hair
thin upper lip and modest micrognathia (c) Chromosome 13 profile from olig
spanning from 37,447,455 -65,319,891 base pairs (for Methods see text).1/6 systolic murmur. Neurological examination showed
developmental delay and hypotonia. At age 2 years and
6 months neuropsychiatric evaluation revealed a de-
velopmental and psychomotor delay. Her height was
79.5 cm (< 3 centile, -2.7 SDS), head circumference
48,5 cm (50th centile), and growth rate 8.56 cm/year
(−0.09 SDS). Physical examination revealed hepato-
megaly and increased liver consistency. Liver ultrasound
revealed a liver mass below the costal arch, affecting
segment V and VI with exophytic course and measuring
57×56×70 mm. At the age of 3 years she underwent a
resection of the liver mass. The histological analysis re-
ferred to a type 1 infantile hemangioendothelioma (IHE)
of the liver. Based on the presence of psychomotor
delay associated with dysmorphism, karyotype analysis
was carried out revealing an interstitial deletion 13q13-
q21.2. Fluorescence In Situ Hybridization (FISH)
confirmed the absence of the RB1 gene. Array-CGH
revealed a 27.87 Mb loss affecting the 13q13.3q21.31 re-
gion, with a proximal breakpoint located on 13q13.3
(position 37,447,455 bp) and a distal breakpoint located
on 13q21.31 (position 65,319,891 bp) according to the
GRCh37/hg19 genome release (Figure 1c). The parents
showed a normal karyotype. She performed a completee 13
in the patient. Frontal (a) and (b) lateral view of the 3-year-old patient
, bilateral epicanthus, broad nasal bridge, short nose with a long philtrum,
o array-CGH showing the 27.87 megabases deletion in 13q13.3q21.31
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retinoblastoma.
Methods
After obtaining an informed consent from her parents,
chromosome analysis was performed from patient’s peri-
pheral blood sample by conventional G-banding techniques
at 500-band level. Fluorescence In Situ Hybridization was
performed using a whole chromosome paint 13(WCP)
probe (VYSIS Inc.) and a combination of subtelomeric
probe specific for chromosome 13q and LSI13 probe on
13q14 (TelVysion VYSIS Inc. USA), according to the
manufacturer’s recommendations. Array-CGH was per-
formed using a whole genome array CytoChip Oligo ISCA
180 K (BlueGnome, Cambridge, UK), containing appro-
ximately 181.000 60-mer oligonucleotides probes. Genomic
DNA was isolated from peripheral blood using the DNeasy
Blood & Tissue Kit (QIAGEN GmbH, Hilden, Germany)
according to standard methods. A sex-matched DNA
(Promega, Madison, UK) was used as reference. Digestion,
labeling and hybridization were performed following the
manufacturer’s protocol (version 1.2) (http://www.cambridge
bluegnome.com/). Slides were scanned using an Agilent
scanner, with a 5 μm resolution. Data were analyzed using
BlueFuse Multi software (BlueGnome, Cambridge, UK).
Discussion
We report on a 3-year-old girl with a 13q13.3q21.31 de-
letion of approximately 28 Mb, including the RB1 gene,
showing developmental delay, short stature, facial dys-
morphism and hemangioendotelioma of the liver with-
out Rb. Her phenotype overlaps with patients falling into
Group 1 of proximal 13q deletions, as defined by Brown
and coworkers [3]. Common features include mild men-
tal retardation, craniofacial dysmorphism (epicanthus,
broad nasal bridge with a long philtrum, thin upper lip)
and inconstant Rb. Additional tumors have not been
clearly documented in over 150 patients cytogenetically
characterized from 1963 to 2007. The first systematic
molecular characterization of 13q deletion was proposed
in 2007 by Ballarati et al. Subsequently, Mitter et al. ana-
lyzed a cohort of 63 Rb patients with a 13q deletion
involving RB1 and observed only few second tumors,
while rare secondary malignancies were present among
patients with Rb treated with chemotherapy [4].
We reviewed in detail patients with molecularly charac-
terized 13q deletions with size and position similar to that
observed in our patient, fitting the group of “large dele-
tions” according to Mitter et al. Two patients aged 1 year
and 5 months and 6 years and 9 months showed bilateral
Rb diagnosed in both cases before the age of 2 years
(17 and 9 months, respectively). They shared several
phenotypic features including facial dysmorphism with
high forehead, short nose, long philtrum, small upper lip,hypotonia and mild cognitive defect [4]. Three additional
patients did not develop Rb. Thienpont et al. described a
16-year-old patient carrying a 13q13.3q21.31 deletion of
25 Mb with postnatal growth retardation, mild psycho-
motor development delay, facial dysmorphism and chronic
constipation [5]. Ballarati et al. reported an 11-year-old
patient with a 13q14.11q21.31 deletion of 22.8 Mb displa-
ying mild mental retardation, motor delay, hypotonia,
epicanthus and a broad prominent nasal bridge, with nor-
mal stature [6]. Tosca et al. described a 3-year-old patient
with similar phenotypic and behavioral features carrying a
13q13.3q21.31 deletion of around 25.27 Mb [7]. These pa-
tients developed neither Rb nor any other tumor.
The mechanisms underlying such a clinical variability,
including the different penetrance of Rb, are far from
being understood but likely reside on the different ge-
netic backgrounds and environmental factors. Interes-
tingly, it appears that patients with deletions larger than
1 Mb (including RB1) have milder phenotypic expres-
sion, consisting in unilateral or absent Rb [4]. Based on
the young age of our patient we cannot exclude that Rb
may develop with time and accordingly she will undergo
periodic ophthalmologic examinations.
Our patient displayed liver IHE, initially suspected at
physical routine examination as an asymptomatic, palp-
able upper abdominal mass. IHE is the most common
benign vascular hepatic tumor in infants, with 85% of
patients diagnosed within the age of 6 months, sugges-
ting a congenital nature of the neoplasia [8]. To the best
of our knowledge, this is the first case of IHE of the liver
reported in literature associated to a 13q deletion, while
a patient with IHE and an interstitial deletion of chro-
mosome 6q was reported [9].
Interestingly, additional neoplasias (other than Rb) are
rarely reported in patients with 13q deletions including
pinealoblastomas, osteosarcomas, lipoma and fibroa-
denoma [4], while loss of heterozygosity at 13q14 is fre-
quently observed in liver cancer [10]. Dehner and Ishak
have classified IHE into two patterns: type 1, a benign
form, and type 2, which can be occasionally malignant
[11]. The histological analysis of the hepatic tumor in
our patient reported the presence of a solitary, circum-
scribed tumor in the right lobe of the liver with micro-
scopic characteristics referring to type 1 IHE, with no
evidence of malignant change. IHE is a rare neoplasia of
mesenchymal origin. Of note several tumors displaying
somatic loss of 13q13-14 are of mesodermal origin,
including blood tumors (leukemias, myelodysplastic syn-
drome and multiple myeloma), uterine leiomyoma and
cartilaginous tumors (chondrosarcoma, enchondroma
and chondromixoid fibroma) [12-16]. Based on the vas-
cular origin of IHE, we considered a possible role in its
pathogenesis of the FoxO1 gene that is included in the
deleted region. FoxO1 is a member of the forkhead box
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vascular stability and suppression of aberrant vascular
outgrowth, and represents one of the effectors of the
PI3K/AKT/mTOR pathway, an established oncogenic
driver in humans [17,18]. Besides these speculations, we
cannot exclude that the co-occurrence of 13q deletion
and IHE is coincidental. Indeed, no clear-cut correlation
has been defined between distinct 13q deleted genes and
cancer, in addition to RB1 in Rb.
In conclusion, we describe the first case of hemangioen-
dothelioma of the liver in a patient carrying a 13q deletion
of approximately 28 Mb who did not develop Rb until the
age of 3 years. The description of further patients with
13q deletions with associated tumors (different from Rb)
will help defining genotype-phenotype correlations.
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